1 We studied the renal effects of reinfusing low dose angiotensin II (1 ng kg-' min-1) into seven salt-replete healthy volunteers after pretreatment with the angiotensin converting enzyme (ACE) inhibitor captopril (25 mg) to establish whether the natriuretic and renal haemodynamic responses to ACE inhibition in normal man result from suppression of circulating angiotensin II. In the same subjects we also studied the effect of captopril (25 mg) with and without exogenous angiotensin II (1 ng kg-' min-') on the natriuretic response to intravenous frusemide (20 mg). 2 In the pre-frusemide study captopril increased absolute and fractional excretion of sodium and paraaminohippurate clearance but had no effect on inulin clearance. 3 Reinfusion of angiotensin II after captopril pretreatment completely suppressed the renal effects of ACE inhibition, yielding renal vasoconstrictor and antinatriuretic effects equivalent to those produced by infused angiotensin II in the absence of captopril. 4 Frusemide increased renal sodium excretion without affecting paraaminohippurate or inulin clearance. Captopril augmented frusemide-induced natriuresis and again this effect was reversed by angiotensin II reinfusion. 5 We conclude that captopril augments both basal and frusemide-induced renal sodium excretion in normal man. Our findings suggest that these renal responses to ACE inhibition may be mediated by inhibition of circulating angiotensin II, specifically its renal tubular salt-retaining actions, rather than via effects on other neurohumoral systems.
Introduction
Controversy exists as to whether the natriuretic response to angiotensin converting enzyme (ACE) inhibitors in normal man (MacGregor et al., 1980) is mediated via antagonism of the circulating renin-angiotensinaldosterone system (RAAS) or whether it results from kinin-mediated (Clappison et al., 1981) or prostaglandinmediated (Usberti et al., 1986 ) effects or via effects on the recently recognised intrarenal tissue RAAS (MacFadyen et al., 1991) .
In the present study we investigated in a group of healthy human subjects pretreated with the ACE inhibitor captopril whether reinfusing exogenous angiotensin II (AII), which replaces circulating but not intrarenal All (Reams et al., 1990) A second aim of our study was to examine the role of circulatory AII in the natriuretic response to the loop diuretic frusemide. Frusemide is known to activate the RAAS (Mackay et al., 1984) but it is unclear whether the resulting elevated AII level assists or opposes the effect of the drug: studies have variably demonstrated that ACE inhibition augments (MacDonald et al., 1989) , blunts (Chiu et al., 1984; Di Nicolantonio et al., 1987; Toussaint et al., 1989) or has no effect (Fujimura & Ebihara, 1988; Kelly et al., 1983) on frusemide-induced natriuresis. In the present study, by investigating the effect of ACE inhibition on frusemide-induced natriuresis with and without reinfusion of exogenous AII, we aimed to determine whether the circulating RAAS facilitates or attenuates the natriuretic response to frusemide. 
Analysis of results
Mean arterial pressure (MAP) was calculated for each 20 min interval from the average of three serial readings as diastolic BP + (systolic BP-diastolic BP)/3. Clearance (C) was calculated for different substances as UV/P where U = urinary concentration, V = urine flow rate and P = plasma concentration. Inulin clearance (CINU) was used as a measure of glomerular filtration rate and PAH clearance (CPAH) as a measure of effective renal plasma flow (ERPF). Osmolar clearance (Cosm) and clearance of sodium (CNa) were also determined as UV/P and free water clearance (CH2O) as V-Cosm. Using these indices the following parameters (expressed as percentages) were then calculated using established formulae: Results for the three separate 20 min urine collection periods after commencement of the AII or placebo infusion and prior to frusemide administration have been expressed as individual means (+95% confidence intervals) for the graphical data but have been expressed as a single mean (+95% confidence interval) over 60 min for the tabular data. A similar format of data expression has been followed for the three 20 min periods post-frusemide.
Pre-frusemide response to captoprillAII (Figure 1 , Table 1) a. Placebo tablet/AII infusion As compared with the placebo/placebo limb, placebo/All caused significant reductions in absolute rate of sodium excretion (UNaV) (P < 0.001), fractional sodium excretion (FENa) (P < 0.05) and ERPF (P < 0.0001) but had no effect on GFR. A rise in renal vascular resistance (RVR) (P < 0.00001) occurred and was associated with a small but significant rise in mean systemic arterial pressure (MAP) (P < 0.0001). A significant reduction in urine flow rate (UV) (P < 0.0001) and an increase in filtration fraction (FF) (P < 0.0001) were observed. Significant reductions in FDDNa, reflecting increased reabsorption of sodium in the proximal nephron (P < 0.0001) and increased (2) 97 (3) Aldosterone (pg ml-') 166 (57) 219 (57) 146 (57) 221 (62) ANF (pmol 1-1) 8.3(1.9) 7.6(1.9) 8.2(1.9) 7.5(2.1) Noradrenaline (pg ml-) 0.68(0. 
Discussion
In this study we have demonstrated that the enhancement of natriuresis by captopril in healthy salt-replete subjects can be reversed completely by reinfusing lowdose All, yielding an absolute sodium excretion rate equivalent to that produced by the same dose of All in the absence of captopril. This suggests that captopril's pronatriuretic effect in salt-replete individuals is mediated by inhibition of AII formation rather than via effects on kinins (Clappison et al. 1981) or prostaglandins (Usberti et al., 1986) . Oral ACE inhibition is known to block both circulating and intrarenal tissue AII (MacFadyen et al., 1991) . We assumed that exogenously infused AII after ACE inhibition would replace only circulating AII and not tissue AII. This assumption is strongly supported by the recent work of Reams et al. (1990) who demonstrated in dogs that while high concentrations of All were measurable in all areas of the renal parenchyma, systemically infused radiolabelled AII was not detectable in any renal tissue. Since infused AII, which replaces only endogenous circulating All and not tissue All, reverses the natriuretic and renal haemodynamic effects of captopril, we suggest that the acute effects of captopril in augmenting natriuresis and renal perfusion are mediated primarily by inhibition of circulating rather than tissue derived All. This suggestion is consistent with the work of de Leeuw et al. (1985) who observed that intrarenal infusion of an ACE inhibitor resulted in an increase in renal blood flow only when systemic ACE was involved and not when intrarenal ACE alone was inhibited.
The lack of any demonstrable change in inulin clearance in response to captopril in our study strongly suggests that captopril's pronatriuretic effect is not mediated via an increase in GFR. Furthermore, the impressive enhancement of fractional sodium excretion by captopril indicates a tubular natriuretic mechanism. The increase in fractional distal delivery and fall in fractional distal reabsorption of sodium in response to captopril support both proximal and distal tubular sites of action respectively.
In our study captopril enhanced by 30% the natriuretic response to intravenous frusemide during the first 20 min clearance period after loop diuretic administration. This effect is proportionately lower than the 60% enhancement of natriuresis by captopril in the pre-diuretic phase, but in absolute terms the effect in the frusemide phase is much greater (700 ,umol min-' increment, vs 90 ,umol min-' increment in pre-diuretic phase). The different baseline levels of natriuresis prior to frusemide administration ( Figure 2) do not limit interpretation of results in the frusemide phase since the different 'basal' levels were produced not by poor experimental control but by the very influence under study, namely ACE inhibitor treatment. Such an effect will be present in any situation, including that encountered in clinical practice, where an ACE inhibitor is given along with a diuretic. Indeed, one could argue that captopril's pronatriuretic effect in the pre-diuretic phase may have resulted in a state of relative sodium depletion, thus leading to an attenuation and underestimation of its enhancing effects on frusemide-induced natriuresis.
This facilitatory effect of captopril on frusemideinduced natriuresis, as in the pre-diuretic phase, was associated with a marked increment in fractional sodium excretion which was completely suppressed by reinfusing AII, suggesting that captopril is again acting by antagonism of the tubular effects of the circulating RAAS. It is most unlikely that captopril's augmentation of frusemideinduced natriuresis is effected simply by increased renal delivery of frusemide secondary to increased renal blood flow: captopril has been shown to decrease by 50% the renal clearance of frusemide in normal man (Toussaint et al., 1989) .
One other group have previously demonstrated that administration of an ACE inhibitor (ramipril) to normal man augments the natriuretic response to frusemide (MacDonald et al., 1989 ) but they did not study the role of the circulating RAAS in mediating this effect by reinfusing All. Instead that group speculated on the importance of renal dopamine in the response, finding that ramipril enhanced the frusemide-induced increase in urinary free dopamine. It is conceivable that both AII and dopamine are important, the ACE inhibitor possibly acting by withdrawal of an inhibitory influence of AII on renal dopamine production.
Interestingly, we observed no increase in either PAH or inulin clearance in response to frusemide and an additional marginal increment in PAH but not inulin clearance following ACE inhibition. MacDonald et al. (1989) found virtually opposite effects, namely increases in PAH and inulin clearances following frusemide administration and a further increment in inulin but not PAH clearance in response to ACE inhibition. We cannot account for this disparity, although the observed haemodynamic effects of frusemide as reported in the literature do vary widely. Furthermore, MacDonald et al. (1989) used 30 mg rather than 20 mg frusemide and Brater (1979) has emphasised the difference in renal effects which can be observed with variation in dose of frusemide.
In summary, we have confirmed that the ACE inhibitor captopril augments renal sodium excretion in normal human subjects both in the non-diuretic treated and loop diuretic treated states. Our results suggest that in mediating these effects captopril acts mainly by inhibition of circulating AII formation rather than via its effects on other neurohumoral systems.
